PLX Overview

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Wall Street analysts forecast PLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLX is12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Protalix Biotherapeutics Inc revenue for the last quarter amounts to 26.33M USD, increased 160.37

Protalix Biotherapeutics Inc. EPS for the last quarter amounts to 0.22 USD, decreased -540.00

Protalix Biotherapeutics Inc (PLX) has 226 emplpoyees as of May 27 2026.

Today PLX has the market capitalization of 172.42M USD.